» Articles » PMID: 28207978

Glomerular C4d Deposits Can Mark Structural Capillary Wall Remodelling in Thrombotic Microangiopathy and Transplant Glomerulopathy: C4d Beyond Active Antibody-mediated Injury: a Retrospective Study

Overview
Journal Transpl Int
Specialty General Surgery
Date 2017 Feb 17
PMID 28207978
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Peritubular capillary C4d (ptc-C4d) usually marks active antibody-mediated rejection, while pseudolinear glomerular capillary C4d (GBM-C4d) is of undetermined diagnostic significance, especially when seen in isolation without concurrent ptc-C4d. We correlated GBM-C4d with structural GBM abnormalities and active antibody-mediated rejection in 319 renal transplant and 35 control native kidney biopsies. In kidney transplants, ptc-C4d was associated with GBM-C4d in 97% by immunofluorescence microscopy (IF) and 61% by immunohistochemistry (IHC; P < 0.001). Transplant glomerulopathy correlated with GBM-C4d (P < 0.001) and presented with isolated GBM-C4d lacking ptc-C4d in 69% by IF and 40% by IHC. Strong isolated GBM-C4d was found post year-1 in repeat biopsies with transplant glomerulopathy. GBM-C4d staining intensity correlated with Banff cg scores (rs = 0.45, P < 0.001). Stepwise exclusion and multivariate logistic regression corrected for active antibody-mediated rejection showed significant correlations between GBM duplication and GBM-C4d (P = 0.001). Native control biopsies with thrombotic microangiopathies demonstrated GBM-C4d in 92% (IF, P < 0.001) and 35% (IHC). In conclusion, pseudolinear GBM-C4d staining can reflect two phenomena: (i) structural GBM changes with duplication in native and transplant kidneys or (ii) active antibody-mediated rejection typically accompanied by ptc-C4d. While ptc-C4d is a dynamic 'etiologic' marker for active antibody-mediated rejection, isolated strong GBM-C4d can highlight architectural glomerular remodelling.

Citing Articles

Re-Evaluating the Transplant Glomerulopathy Lesion-Beyond Donor-Specific Antibodies.

Chutani A, Guevara-Pineda D, Lerner G, Menon M Transpl Int. 2024; 37():13365.

PMID: 39640250 PMC: 11617188. DOI: 10.3389/ti.2024.13365.


Transplant Glomerulopathy: Importance of Ultrastructural Examination.

Gibson I Glomerular Dis. 2023; 1(2):68-81.

PMID: 36751426 PMC: 9677739. DOI: 10.1159/000513522.


Glomerular C4d Immunoperoxidase in Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy.

Nankivell B, PNg C, Shingde M Kidney Int Rep. 2022; 7(7):1594-1607.

PMID: 35812271 PMC: 9263257. DOI: 10.1016/j.ekir.2022.04.016.


The Proteome of Antibody-Mediated Rejection: From Glomerulitis to Transplant Glomerulopathy.

Chauveau B, Raymond A, Di Tommaso S, Visentin J, Vermorel A, Dugot-Senant N Biomedicines. 2022; 10(3).

PMID: 35327371 PMC: 8945687. DOI: 10.3390/biomedicines10030569.


Caveolin-1 in Kidney Chronic Antibody-Mediated Rejection: An Integrated Immunohistochemical and Transcriptomic Analysis Based on the Banff Human Organ Transplant (B-HOT) Gene Panel.

Gambella A, Barreca A, Osella-Abate S, Bottasso E, Giarin M, Papotti M Biomedicines. 2021; 9(10).

PMID: 34680435 PMC: 8533527. DOI: 10.3390/biomedicines9101318.